(Bloomberg) -- Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

Pfizer also has experienced multiple setbacks in its attempts to develop ... Nurtec ODT for migraine and Xtandi for prostate cancer. Adjusted earnings for 2024 will be $2.75 to $2.95 a share ...

Pfizer recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced ...

is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside Xtandi, reduced prostate cancer progression by 49%. The data ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

On the regulatory front this year, a Pfizer spokesperson said the company anticipates three regulatory decisions in prostate cancer, colorectal cancer and non-Hodgkin lymphoma, as well as seven Phase ...

This isn't the first setback for Pfizer's danuglipron, either. The company scrapped development of its twice-daily weight-loss pill in 2023 after a clinical trial showed "high rates" of adverse ...

cervical and prostate cancers. “At Pfizer, we partner across the oncology community to meet the needs of people with cancer and help everyone have access to quality cancer care,” said Jeffrey ...

Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle ... joins us to discuss the recent setbacks and wins in oncology R&D ...